You are viewing a preview of...

Non-Antibiotic Antimicrobial for Treatment of Respiratory Infections

A suite of antimicrobials with a novel mechanism of action to treat COVID-19 associated secondary infections

Background

Antimicrobials, such as antibiotics, have had perhaps the most dramatic impact on modern medicine. Due to overuse and misuse, resistance to conventional antibiotics is rising dramatically. To overcome such resistant strains and to slow the emergence of new resistant microorganisms, there is an urgent pressing need for innovative new classes of antimicrobials.

Antimicrobial resistance is a major health problem which is expected to grow dramatically in the coming years. The CDC in their Antibiotic Resistance Threats Report in 2019 state that over 2.8 million antibiotic-resistant infections occur in the US each year, responsible for greater than 35,000 deaths. Globally over 700,000 people die each year from antibiotic resistance. The O’Neill Report commissioned by the UK government have suggested that

Log in or create a free account to continue reading